Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease

Wen Hsin Chang, Dau Ming Niu, Chi Yu Lu, Shyr Yi Lin, Ta Chih Liu, Jan Gowth Chang

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

While a base substitution in intron 4 of GLA (IVS4+919G>A) that causes aberrant alternative splicing resulting in Fabry disease has been reported, its molecular mechanism remains unclear. Here we reported that upon IVS4+919G>A transversion, H3K36me3 was enriched across the alternatively spliced region. PSIP1, an adapter of H3K36me3, together with Hsp70 and NONO were recruited and formed a complex with SF2/ASF and SRp20, which further promoted GLA splicing. Amiloride, a splicing regulator in cancer cells, could reverse aberrant histone modification patterns and disrupt the association of splicing complex with GLA. It could also reverse aberrant GLA splicing in a PP1-dependant manner. Our findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future.

Original languageEnglish
Article numbere0175929
JournalPLoS ONE
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 2017

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease'. Together they form a unique fingerprint.

Cite this